Outlook Therapeutics Insider Bets $5 Million as FDA Clears Path for Eye Drug

A director at Outlook Therapeutics has put more than $5 million of his own money on the line, scooping up 8.54 million shares at an average price of $0.59 each in late May. The purchase by Ghiath M. Sukhtian came days before the company announced a major regulatory win: the US Food and Drug Administration had reversed its earlier demand for additional clinical trials on Lytenava, the firm’s experimental treatment for wet age-related macular degeneration.

The insider vote of confidence was prescient. Shares of the micro-cap biotech have more than doubled since early spring, initially surging 57% after the FDA confirmed the drug’s efficacy data, then tacking on another nearly 15% when the agency formally backed down from its study requirement. At the time of the director’s buy, the stock traded at $0.59 — well below the $10.00 price target still held by analysts at Ascendiant Capital Markets.

The FDA’s about-face clears the way for a streamlined approval process. Outlook Therapeutics has already resubmitted its Biologics License Application, filed in June, and the regulator has granted it Class 1 priority review. That designation slashes the review timeline, with a final decision expected in the third quarter of 2026 — within roughly 60 days. If approved, Lytenava would become the first FDA-authorized ophthalmologic formulation of bevacizumab, a widely used cancer drug that doctors currently repackage from intravenous vials for off-label eye injections.

Should investors sell immediately? Or is it worth buying Outlook Therapeutics?

The financial stakes are high. At the end of March, Outlook held just $7.7 million in cash, barely enough to cover one quarter’s operating expenses. The company raised $10 million through share sales and investor funds in May, but that capital also faces rapid burn. First-quarter results underscored the pressure: revenues came in at a mere $130,000 against market expectations of $4.39 million, while the net loss per share of $0.16 missed analysts’ consensus forecast of a $0.12 loss. Still, Ascendiant sees improvement ahead, trimming its third-quarter 2026 loss estimate to $0.10 a share from an earlier projection of $0.14.

Beyond the US, Outlook is already pushing ahead with commercialization. Lytenava has secured approval in Europe and the United Kingdom, and the company has initiated marketing efforts there. That international foothold provides a hedge against potential delays stateside, though the real prize remains the American market.

The next few weeks will determine whether Outlook Therapeutics can shed its development-stage status and become a commercial biotech. With the FDA now engaged in direct negotiations over the final prescribing label, and a priority review clock ticking, the summer of 2026 is shaping up as the company’s make-or-break moment.